Themis Medicare gets add on approval for drug VIRALEX; Stock plunges over 5%

Themis Medicare Ltd. (Themis), a Pharmaceutical firm headquartered in Mumbai has introduced the add on approval for drug VIRALEX by the Drug Controller Common of India (DCGI) for remedy of Influenza and different Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

VIRALEX (Inosine Pranobex) is an immunomodulatory agent with broad spectrum antiviral properties. Earlier VIRALEX was authorised by DCGI for restricted emergency use in Covid 19 sufferers primarily based on the outcomes of two Randomized managed trials (RCT) in 499 Indian sufferers.

Inosine Pranobex is in medical use for >50 years since its first approval internationally. It’s at present marketed in >70 international locations the world over together with many advance international locations for the remedy of a number of viral illnesses with established efficacy and security profile.

VIRALEX strengthens the immune system by modulation of T-cell proliferation, T-cell operate, pure killer cell exercise, phagocytosis, and likewise by modulating sure cytokines, and enhances physique’s immune response to numerous viral infections.

NK cells are the primary line protection in opposition to viral infections. VIRALEX enhances human NK cell cytotoxicity in two methods by growing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Primarily based on world extensive expertise, the drug supply medical advantages to the sufferers and deal with the unmet medical want in administration of assorted viral infections, particularly influenza and AVRI.

In accordance with Themis, VIRALEX is manufactured at an EU-GMP-certified facility with the best security requirements and stringent manufacturing protocols in place, and the remedy is out there on prescription within the type of a 500 mg pill at an inexpensive worth.

At round 10:46 AM, Themis Medicare was buying and selling at Rs826.95 apiece down by Rs48.05 or 5.49% from its earlier closing of Rs875 apiece on the BSE.